KUALA LUMPUR (Nov 24): IHH Healthcare Bhd said there have been discussions on the strategic directions of its investments in China but no decision has been made yet, in response to an article.

A report by Bloomberg said the group is weighing the sale of Parkway China for as much as US$1 billion (RM4.2 billion), quoting sources.

“IHH wishes to clarify that it constantly reviews and assesses the strategic direction of IHH Group’s investments. In relation to IHH Group’s investments in China, there have been discussions on the strategic directions but no definitive decisions have been made as at the date of this announcement.

“Any proposals with regards to IHH Group’s investment in any subsidiaries would have to be considered and decided by the Board of Directors of IHH and/or its relevant subsidiaries,” said the group in its filing with the bourse.

The group said it will make the appropriate announcements to the bourse, if there are any material developments.

IHH Healthcare fell one sen or 0.2% to RM6.69 on Wednesday (Nov 24), giving it a market capitalisation of RM58.81 billion.